(Reuters) - The board of Biosite told Beckman that it considered a $92.50 per share bid by Inverness, which makes home pregnancy tests and fertility monitoring kits, as superior, Beckman said.
Beckman, which makes genetic analysis testing systems, said it believed that the long-term interests of its shareholders would not be served by increasing its bid.
Read more at Reuters.com Business News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment